Two NIH Institutes Will Fund New Synchrotron Beamlines

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Jacob Sands, MD

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Russ Conroy

Navigating Second-Line Treatment Options in Urothelial Carcinoma

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana LLC.

INKmune Exhibits Favorable Safety in Metastatic CRPC

The complete response letter for the agent is due to observations from an FDA general site inspection at Catalent Indiana LLC.

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

Roman Fabbricatore

TIL Therapy Provides Excitement Despite Room to Grow in Melanoma Care

Developers plan to initiate a phase 2b trial in patients with less severe prostate cancer variants to better assess INKmune’s antitumor effects.

Related Content

Integrating Dato-DXd Into Early-Line EGFR-Mutant NSCLC Management

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Jacob Sands, MD

Developing a Bridge to Optimize Cellular Therapy Use in Multiple Myeloma

Jacob Sands, MD, discussed considerations for EGFR-mutant non–small cell lung cancer following the approval of dato-DXd in this disease.

Russ Conroy

Navigating Second-Line Treatment Options in Urothelial Carcinoma

More work is needed to expand access to novel CAR T-cell therapies and bispecific agents among community oncologists, according to Al-Ola A. Abdallah, MD.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

FDA Issues CRL to Odronextamab in Pretreated Follicular Lymphoma

Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, focus on treatment options for patients with urothelial carcinoma.